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Abstract
In patients with chronic idiopathic cough, there is a chronic inflammatory response together with
evidence of airway wall remodelling and an increase in airway epithelial nerves expressing TRPV-1.
We hypothesised that these changes could result from an increase in growth factors such as TGF
and neurotrophins.
We recruited 13 patients with persistent non-asthmatic cough despite specific treatment of
associated primary cause(s), or without associated primary cause, and 19 normal non-coughing
volunteers without cough as controls, who underwent fiberoptic bronchoscopy with
bronchoalveolar lavage (BAL) and bronchial biopsies.
There was a significant increase in the levels of TGF in BAL fluid, but not of nerve growth
factor(NGF) and brain-derived nerve growth factor(BDNF) compared to normal volunteers. Levels
of TFG gene and protein expression were assessed in bronchial biopsies. mRNA expression for
TGF was observed in laser-captured airway smooth muscle and epithelial cells, and protein
expression by immunohistochemistry was increased in ASM cells in chronic cough patients,
associated with an increase in nuclear expression of the transcription factor, smad 2/3.
Subbasement membrane thickness was significantly higher in cough patients compared to normal
subjects and there was a positive correlation between TGF- levels in BAL and basement
membrane thickening.
TGF in the airways may be important in the airway remodelling changes observed in chronic
idiopathic cough patients, that could in turn lead to activation of the cough reflex.
Background
Chronic cough is a common clinical problem [1,2].
Asthma, postnasal drip or rhino-sinusitis, and gastro-
oesophageal reflux have been recognized as being the
most common causes of chronic cough [2,3]. In some
patients, no cause can be identified despite thorough
investigations and empiric treatment [4-6], a group
recently denoted as 'idiopathic'. Patients with chronic
cough very often demonstrate an increased tussive
response to inhalation of tussive agents such as capsaicin
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indicates that there is a sensitisation of the cough reflex
[7]. Both peripheral and central causes of this sensitisa-
tion have been put forward[8,9]; however, changes
observed in the airways of patients with chronic cough
indicate that peripheral changes could be involved in the
sensitisation of the cough reflex. Thus, there is an increase
in mediator expression as measured by increased levels of
histamine in bronchoalveolar lavage fluid, and levels of
cys-leukotrienes, leukotriene B4, myeloperoxidase and
TNF in induced sputum samples from patients with per-
sistent cough [10]. Examination of bronchial biopsies
from non-asthmatic chronic cough patients reveal an
increase in mast cells in the submucosa, with also marked
changes in airway wall remodelling such as subepithelial
fibrosis, goblet cell hyperplasia and blood vessels, similar
to that observed in patients with asthma, together with an
increase in airway smooth muscle cells [11]. Perhaps of
greater relevance to the enhanced cough reflex are abnor-
malities in the epithelial nerve profiles which could repre-
sent cough receptors. Although there are no increases in
nerve profiles, the expression of the neuropeptide, calci-
tonin gene-related peptide (CGRP), and of the ion chan-
nel, transient receptor potential vanniloid 1 (TRPV1), has
been reported to be increased in these epithelial nerves
[12,13].
To explore further the role of airway wall remodelling and
of peripheral neural plasticity in chronic cough, we have
measured in bronchoalveolar lavage fluid the levels of
growth factors, such as transforming growth factor-
(TGF), which may be involved in subepithelial fibrosis
[14], and of the neurotrophins such as brain-derived neu-
rotrophin (BDNF) which may elicit sensitisation of noci-
ceptors [15], and angiogenesis and microvascular
remodelling [16]. We also examined the expression of
TGF in airways submucosa of chronic idiopathic cough
patients.
Methods
Subjects
We studied patients with chronic cough of at least 8
weeks' duration referred to our cough clinic and excluded
patients who had a diagnosis of asthma as a cause of their
cough (Table 1). As a control group, we recruited normal
volunteers through local advertisement; these normal vol-
unteers had no previous history of cough or asthma, and
were not suffering from any intercurrent illness.
Patients with chronic cough underwent diagnostic evalu-
ation that included chest radiograph, pulmonary function
test, methacholine challenge, 24-hour oesophageal pH-
monitoring, and chest and sinus computed tomogra-
phy[1]. Patients with airway hyperresponsiveness (pro-
vocative concentration of methacholine that induced a >
20% decrease of forced expiratory flow in 1 second (FEV1)
[PC20- FEV1] < 4 mg/ml), diurnal variation of peak expir-
atory flow (> 20%), or > 15% increase of FEV1 after -ago-
nist, and also response of coughing to inhaled
bronchodilator and corticosteroid therapy were diag-
nosed as having asthma responsible for chronic cough,
and they were excluded from the study. The patients with
Table 1: Patient characteristics
Normals Chronic cough
Number 13 20
Gender (Male/Female) 9:4 4:16**
Age (years) 19.9 ± 0.4 55.4 ± 2.5**
Smoking status (n)
never 12 11
ex-smoker 1 9
Pack-years 7 13.1 ± 3.5
GORD (n) NA 10
Postnasal drip (n) NA 7
Neither (n) NA 5
Atopy (%) 31 26
Capsaicin (log10 C5) ND 0.53 ± 0.14
FEV1 (% predicted) 96.0 ± 3.3 99.0 ± 2.3
FVC (% predicted) 100.5 ± 3.3 96.8 ± 4.6
Bronchoalveolar lavage
% macrophages 97.6 ± 0.5 90.1 ± 2.6**
% neutrophils 1.5 ± 0.4 6.7 ± 2.6*
% lymphocytes 0.7 ± 0.2 3.0 ± 0.8**
% eosinophils 0.3 ± 0.1 0.2 ± 0.1
FEV1: Forced expiratory volume in one second; FVC: Forced vital 
capacity; GORD: gastro-oesophageal reflux disease; NA: Not 
applicable; ND: Not done. Data shown as mean ± SEM. * p < 0.05; **p 
< 0.01.Respiratory Research 2009, 10:40 http://respiratory-research.com/content/10/1/40
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chronic cough recruited to this study had a PC20 FEV1 > 8
mg/ml. Chronic cough due to gastro-oesophageal reflux
was diagnosed by 24-hour oesophageal pH-monitoring
and efficacy of 12-week course of proton-pump inhibitor,
and dietary changes. Chronic cough was attributed to
post-nasal drip/rhinosinusitis when symptoms and objec-
tive diagnosis of postnasal drip and/or rhinosinusitis were
present and nasal corticosteroids and/or nasal anticholin-
ergics were effective against cough. Some patients had no
identifiable cause(s) of cough despite additional investi-
gations including bronchoscopy and intensive therapeutic
trials for asthma, gastro-esophageal reflux and postnasal
drip/rhinosinusitis, and were labelled as 'idiopathic'.
Only ex-smokers who have ceased smoking more than 12
months of enrolled were recruited.
The study was approved by the Ethics Committee of our
institution and all subjects gave informed consent to par-
ticipate in the study.
Capsaicin challenge
As previously described [17], coughs were counted for one
minute after single-breath inhalations of 0.9% sodium
chloride and capsaicin solutions of increasing concentra-
tions (0.98 to 500 M). They were generated from a
dosimeter (P.K.Morgan Ltd, Gillingham, UK) set at a dos-
ing period of 1 second. This was continued until 5 or more
coughs were induced. The concentration that caused 5 or
more coughs was recorded (C5) and the data analysed as
log10 C5.
Bronchoscopy, bronchoalveolar lavage and bronchial 
biopsy
Bronchoscopy was performed as previously described
[18]. Briefly, subjects were pretreated with intravenous
midazolam (5 mg). Oxygen was administered via nasal
prongs throughout the procedure. Using local anesthesia
with 2% lidocaine to the upper airways and larynx, a fibr-
eoptic bronchoscope (Olympus BF 10, Key-Med, Herts,
UK) was passed through the nasal passages into the tra-
chea. Warmed 0.9% NaCl solution (50 ml × 4) was
instilled into the right middle lobe and BAL fluid was
retrived by gentle suction. The supernatant was recovered
after centrifugation of the fluid and kept at -70C in aliq-
uots of 5 mls until assayed. Washed BAL cells were sus-
pended in culture media and counted on a
hemocytometer. Cytospins were stained with DiffQuick
stain for differential cell counts. Three to 5 mucosal
biopsies were taken from the segmental and subsegmental
bronchi of the right lower lobe.
Measurement of TGF-1, NGF and BDNF in BAL fluid
The concentrations of TGF-1, NGF and BDNF in BALFs
were measured by ELISA kits according to the manufac-
turer's instructions (R&D System or Promega for BDNF).
For TGF-1 assay, BALFs were first activated by incubation
with 1N HCl for 10 min and neutralized by 1.2 N NaOH/
0.5 M N-2-hydroxyethylpiperazine-N'-ethane sulfonic
acid. Activated samples were then transferred to the wells
of plates coated with TGF-1 soluble receptor Type II. For
NGF and BDNF assay, plates were coated with anti-
human -NGF or BDNF antibody. 100 l of BALFs were
added to each well. After incubation and thorough wash-
ing, specific antibody for each measurement was added to
the test wells. TGF-1, NGF and BDNF were detected
using a horseradish peroxidase-based colorimetric assay.
Laser Capture Microdissection
Human airway biopsies were embedded in Optimum
Cutting Temperature compound (OCT) on dry ice and
snap-frozen in liquid nitrogen before storage at -80°C.
Frozen sections were cut at 6 m thickness and mounted
on Laser Capture Microdissection (LCM) slides (Arcturus,
Mountain View, California, US). The slides were immedi-
ately stored on dry ice and then at -80°C until used. Sec-
tions were fixed in 70% ethanol for 30 seconds, and
stained and dehydrated in a series of graded ethanol fol-
lowed by xylene using HistoGene LCM frozen section
staining kit (Arcturus) according to the manufacturer's
instruction. Airway smooth muscle (ASM) cells or epithe-
lial cells were captured onto the CapSure HS LCM caps
(Arcturus) by a Pixcell II Laser Capture Microdissection
System (Arcturus).
Real-time PCR
Total RNA was extracted by using a PicoPure RNA isola-
tion kit (Arcturus) according to the manufacturer's
instructions and was reverse transcribed to cDNA (Robo-
Cycler, Stratagene, USA) using random hexamers and
AMV reverse transcriptase (Promega). cDNA was ampli-
fied by quantitative real-time polymerase chain reaction
(PCR) (Rotor Gene 3000, Corbett Research, Australia)
using SYBR Green PCR Master Mix Reagent (Qiagen). The
human TGF-1 forward and reverse primers were 5'-
CCCAGCATCTGCAAAGCTC-3' and 5'-GTCAATGTA-
CAGCTGCCGCA-3'. Each primer was used at a concentra-
tion of 0.5 M in each reaction. Cycling conditions were
as follows: step 1, 15 min at 95°C; step 2, 20 sec at 94°C;
step3, 20 sec at 60°C; step 4, 20 sec at 72°C, with repeat
from step 2 to step 4 for 40 times. Data from the reaction
were collected and analysed by the complementary com-
puter software (Corbett Research, Australia). Relative
quantitations of gene expression were calculated using
standard curves and normalized to 18S rRNA in each
sample.
Immunohistochemistry
Immunohistochemistry was performed to detect the pro-
tein expression of TGF-1 in human bronchial tissue sec-
tions. Bronchial biopsies were embedded in OCT andRespiratory Research 2009, 10:40 http://respiratory-research.com/content/10/1/40
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stored at -80°C before use. Frozen sections (6 m) were
cut before fixed in cold acetone for 10 min. Sections were
incubated in 10% normal horse serum to block non-spe-
cific binding, followed by a mouse anti-human TGF-1
antibody (1 g/ml, AbCam ab1279) for 1 hour at room
temperature. Control slides were performed with normal
mouse immunoglobulin. Anti-mouse biotinylated sec-
ondary antibody (Vector ABC Kit, Vector Laboratories)
was applied to the sections for 1 hour at room tempera-
ture, followed by 1.6% hydrogen peroxide to block
endogenous peroxidase activity. Sections were incubated
with the avidin/biotinylated peroxidase complex for 30
min, followed by chromogenic substrate diaminobenzi-
dine for 3 min, and then counterstained in haematoxylin
and mounted on aqueous mounting medium. Immuno-
reactivity for TGF-1 was expressed as intensity of staining
that was graded from 0 to 4. Slides were read blindly.
Subbasement membrane thickness
Frozen sections were stained with haematoxylin and
eosin. Subbasement membrane thickness was assessed
(NIH Image analysis 1.55) by measuring 40 point-to-
point repeated measurements at 20 m intervals per
biopsy and the mean thickness calculated as previously
reported [19].
Immunofluorescence and laser scanning confocal 
microscopy
Immunofluorescence was carried out to detect the nuclear
translocation of Smad2/3 in human bronchial biopsy sec-
tions. The sections were fixed with 2% paraformaldehyde
for 10 min at room temperature before incubating in 5%
normal donkey serum to block non-specific binding.
Smad2/3 activation was detected using the rabbit polyclo-
nal antibody for Smad2/3 (1:50, Upstate 07–408, Wat-
ford, UK) for 1 hour at room temperature. Sections were
then incubated with a rhodamine-conjugated donkey
anti-rabbit IgG (1:100) for 45 min in the dark and coun-
terstained with DAPI solution. Sections were photo-
graphed with a laser scanning confocal microscope.
Data analysis
Data were analysed by unpaired non-parametric t-test.
Results are expressed as mean ± SEM. P < 0.05 was taken
as statistically significant.
Results
Table 1 shows the characteristics of the chronic cough
patients and the control volunteers who underwent the
fiberoptic bronchoscopic procedure. The control group
was significantly younger than the chronic cough group.
In the chronic cough group. Ten and 7 patients had an
associated diagnosis of gastro-oesophageal reflux and
postnasal drip respectively, and in 5, no such associated
cause was found.
TGF-1, NGF and BDNF levels in BAL fluid
BAL levels of TGF-1 were significantly higher in chronic
cough compared to those from non-coughing controls
(Figure 1). The mean level was 1.7-fold higher, but in
nearly half of the chronic cough patients, the levels were
significantly higher.
BDNF levels were not different between the two groups,
and levels of NGF were below the limit of detection (Fig-
ure 1). There was a negative correlation between the levels
of BDNF and those of TGF-1 in the chronic cough
patients (r = -0.67; p < 0.01), indicating that high levels of
BDNF were associated with low levels of TGF-1. There
was no correlation between age and the levels of any of
Activated TGF-1 (Panel A) and BDNF (Panel B) levels in  bronchoalveolar lavage fluid (BALF) from 13 normal subjects  and 20 chronic cough patients Figure 1
Activated TGF-1 (Panel A) and BDNF (Panel B) lev-
els in bronchoalveolar lavage fluid (BALF) from 13 
normal subjects and 20 chronic cough patients. **p < 
0.005 compared with normal control. NS: not significant. 
Horizontal bar shows mean.
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Expression of TGF1 protein in bronchial biopsies Figure 2
Expression of TGF1 protein in bronchial biopsies. Examples of TGF1 expression in biopsies from normal (Panel A) 
and from chronic cough patients (Panels B and C) patients. There is increased staining for TGF in the airway smooth muscle 
and epithelial cells in the biopsies from chronic cough patients. Negative control where the primary antibody has been replaced 
by normal rabbit immunoglobulin does not show any staining (not shown). Magnification is ×400 for Panels A and B, ×200 for 
Panel C. Panel D. Immunostaining intensity for TGF1 (grade 0 to 4) in epithelium (EPI) and in airway smooth muscle (ASM) 
from 10 normal and 16 cough patients. **p < 0.01, *p < 0.05; horizontal bar shows the mean.Respiratory Research 2009, 10:40 http://respiratory-research.com/content/10/1/40
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these growth factors in BALF. There was no correlation
between log C5 and TGF1 or BDNF levels in BALF.
TGF-1 protein expression in bronchial biopsies
In view of the increase in TGF-1 levels in BALF from
chronic cough patients, we next performed immunohisto-
chemistry in the biopsy samples from 10 normal and 16
cough donors. TGF-1 expression was enhanced in airway
smooth muscle and epithelium of chronic cough patients
compared with normal controls (Figure 2). TGF- immu-
nostaining intensity was higher by 2-fold and 1.6-fold in
ASM (p = 0.009) and epithelium (p < 0.02), respectively,
of chronic cough patients compared to normal controls
(Figure 2B). There was no positive staining in the negative
control sections in which the mouse anti-TGF-1 anti-
body was replaced by normal mouse immunoglobulin
(Figure 2A).
TGF-1 mRNA in laser-captured airway smooth muscle 
and epithelium
We further examined whether the increased expression of
TGF- protein was related to increased mRNA level in
smooth muscle and epithelium of bronchial biopsies
from 4 chronic cough patients and 4 controls. These in-
situ airway smooth muscle and epithelial cells expressed
TGF-1 mRNA, with a trend for a greater level of expres-
sion in cells from chronic cough patients but statistical
significance was not achieved (Figure 3A &3B).
Subbasement membrane thickness
Subbasement membrane thickness was significantly
increased in chronic cough patients compared to healthy
controls (p < 0.0001; Figure 4A) There was a positive cor-
relation between subbasement membrane thickness and
TGF- levels in BAL fluid (n = 13; r = 0.82; p < 0.0006; Fig-
ure 4B), but not with the intensity of TGF- staining in the
biopsies.
Smad2/3 activation in bronchial biopsies
Because TGF- induces Smad2/3 phosphorylation and
nuclear translocation, we examined for the presence of
Smad2/3 activation using immunofluorescence confocal
microscopy for nuclear staining. The level of Smad2/3
activation expressed as % of nuclear staining cells was
higher in ASM cells of chronic cough patients compared
with normal controls (p < 0.05) (Figure 5A &5B). There
was no difference of Smad2/3 nuclear staining in airway
epithelium between chronic cough patients and normal
controls.
Discussion
We found that TGF levels were increased in bronchoalve-
olar lavage fluid and also in immunohistochemical sec-
tions of the bronchial mucosa, particularly expressed in
the airway epithelium and airway smooth muscle cells
from patients with chronic idiopathic cough compared to
normal volunteers. These indicate that there is an
increased amount of TGF expressed in the airways that
could be involved in the airway wall remodelling of
chronic cough. This is supported by the findings of a pos-
itive correlation between subbasement membrane thick-
ness and TGF- levels in BAL. In addition, the increased
activation of smad 2/3 observed in the bronchial tissues
also indicate that TGF is may be active. Of particular
interest, an increase in TGF has also been reported in BAL
fluid from asthma patients, but none of the patients with
chronic cough had any features of chronic asthma that
could be underlying their cough.
An increased expression of TGF has also been reported in
the airway epithelium and airway smooth muscle cells of
patients with asthma [20,21]. We examined for the pres-
TGF-1 mRNA expression in airway smooth muscle (Panel  A) and epithelial cells (Panel B) obtained by laser capture  microdissection Figure 3
TGF-1 mRNA expression in airway smooth muscle 
(Panel A) and epithelial cells (Panel B) obtained by 
laser capture microdissection. TGF-1 mRNA expres-
sion measured by real-time RT-PCR and expressed as a ratio 
of 18S rRNA is shown for a sample of 4 normal and 4 
chronic cough patients. There was no significant difference.
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ence of TGF mRNA expression in the airway epithelial
cells and airway smooth muscle cells using the technique
of laser capture for the first time, allowing us to specifi-
cally pinpoint the expression of TGF in these selected
cells. However, no significant differences in TGF gene
expression were observed in patients with chronic cough
compared to normal volunteers; however, the number of
patients in each group was probably too small to be con-
clusive. However, we can be confident that there is TGF
gene expression present in the basal state in these airway
cells, but cannot be definite as to the differences in expres-
sion of TGF message. Levels of BDNF in BAL fluid were
not increased and levels of NGF were undetectable. This is
in agreement with a previous study that measured neuro-
trophin levels in the supernatants of induced sputum, and
found no differences between the chronic coughers and
controls [22].
Although the control group of non-coughing volunteers
was not balanced in terms of age and gender as compared
to the chronic cough patients, it showed no evidence
asthma or of chronic airflow obstruction. The difference
in TGF levels is unlikely to be explained by age or gender
differences since there was no correlation between age and
TGF levels or differences in levels of TGF between the
male and female gender. This discrepancy occurred as a
result of difficulty in recruiting non-smoker controls par-
ticularly middle-aged women to undergo fiberoptic bron-
choscopy. Nine out of the 20 chronic cough patients were
ex-smokers and how this could have influenced the
expression of TGF in our studies is unclear. A previous
study has in fact shown that TGF expression is increased
in smoking COPD patients compared to smoking non-
COPD patients[23]. None of our patients showed evi-
dence of chronic airflow obstruction.
The patients with chronic cough recruited in the present
study did not respond to any specific treatment of associ-
ated causes such as asthma, gastrooesophageal reflux and
postnasal drip. No diagnostic cause of the cough could be
determined in all patients. Often, an empirical treatment
of the common causes of cough had been given, namely
asthma treatments with inhaled corticosteroids, or proton
pump inhibitors or nasal corticosteroids. These patients
have all been categorised as having an idiopathic cough,
in whom we could not find a treatable cause or a cause
that is responsive to specific therapies of their cough. This
condition of 'idiopathic' cough can range from 7 to 46%
of all patients attending cough clinics where a thorough
systematic diagnostic work-up is performed[1]. A possible
explanation of the cause of idiopathic cough is that the
initiating cause of the cough may have disappeared, but
its effect in enhancing the cough reflex may be more pro-
longed. An example would be the transient appearance of
an upper respiratory tract virus infection or an exposure to
toxic fumes, that results in prolonged damage of the air-
ways mucosa. The cough becomes 'idiopathic' when the
primary inciting cause has resolved while cough is persist-
ent. The repetitive mechanical and physical effects of
coughing bouts on airway cells could activate the release
of various chemical mediators that could enhance chronic
cough through inflammatory mechanisms, providing a
positive feed-forward system for cough persistence. There
may be an induction in the upper airways of inflamma-
tion and tissue remodelling induced by various causes
associated with cough or by the act of coughing itself that
Subbasement membrane thickness Figure 4
Subbasement membrane thickness. Panel A shows 
increased subbasement membrane thickness in chronic 
cough patients compared to normal controls(* p < 0.0001). 
The horizontal bar shows the mean value. Panel B shows that 
the subbasement membrane thickness correlated with TGF-
 levels in bronchoalveolar lavage fluid (r = 0.82, p < 0.001).
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could lead to an enhanced cough reflex, that in turn is
responsible for maintaining cough.
Previous studies have reported that mucosal biopsies
taken from a group of non-asthmatic patients with
chronic dry cough showed evidence of epithelial desqua-
mation and inflammatory cells, particularly lymphocytic
inflammation, and also by an increase in submucosal
mast cells, but not of neutrophils or eosinophils, with
goblet cell hyperplasia, subepithelial fibrosis and
increased vascularity [24]. Increased mast cells have been
observed also in bronchoalveolar lavage fluid [25] and
increased neutrophils in induced sputum [26], with
increased concentration of histamine, PGD2 and PGE2,
together with TNF and IL-8 in induced sputum [27].
These inflammatory changes may not be specific for idio-
pathic cough because they could represent the sequelae of
chronic trauma to the airway wall following repeated epi-
sodes of cough. It is also possible that chronic airway wall
remodelling may represent the effects of the putative aeti-
Smad2/3 expression in bronchial biopsies Figure 5
Smad2/3 expression in bronchial biopsies. Panel A. Immunofluorescence pictures from confocal microscopy for Smad2/3 
activation (red fluorescence) from human bronchial biopsy sections. Nuclei are stained blue with DAPI. For the negative con-
trol, the primary antibody was replaced by a normal rabbit immunoglobulin. ASM: airway smooth muscle; EPI: epithelium. Panel 
B: % of cells with positive nuclear staining for Smad 2/3 in bronchial biopsies from 6 normal and 7 chronic cough patients. *p < 
0.05 compared with normal control. NS: not significant.
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ological factor for cough, namely growth factors released
that induced the remodelling changes, and also that could
change cough receptor sensitivity.
Release of growth factors such as those of the nerve
growth factor family may lead to alterations in the pheno-
type of neural tissues. Nerve growth factor (NGF) may
increase the expression of calcitonin gene-related peptide
(CGRP) [28] and TRPV-1 [29] in nerves. Elevation of
CGRP and TRPV-1 has been reported in airway epithelial
nerves in chronic cough [12,13]. However, there is no evi-
dence for an increase in NGF levels in BAL fluid or
induced sputum supernatants [21].
Our work supports a new concept regarding the persist-
ence of chronic idiopathic cough through the activation of
TGF-. Airway epithelial cells may produce growth factors
such as TGF- and endothelin and epidermal growth fac-
tor (EGF)-like growth factors when subjected to mechani-
cal stress or pressure [30,31]. Therefore, the repetitive
mechanical and physical effects of coughing bouts on the
airway cells, particularly the airway epithelium, may be
responsible for the increased release of TGF. This possi-
bility is supported by a recent study that showed that trau-
matic mechanical stress to the large airways can induce a
neutrophilic airway inflammation together with cough
reflex hypersensitivity [32]; however, the expression of
TGF was not examined in this study.
TGF has been implicated as a growth factor in the remod-
elling of the epithelial-mesenchymal trophic unit as it can
induce the expression of extracellular matrix components
[33]. In addition, TGF can induce the proliferation and
hypertrophy of airway smooth muscle cells [34,35], and
since these cells also express TGF, as demonstrated in the
current study, potential autocrine effects are also possible.
TGF can also induce mesenchymal cells such as fibrob-
lasts and airway smooth muscle cells to release chemok-
ines such as IL-8/CXCR8, eotaxin/CCR3 or monocyte
chemoattractant protein-1(MCP-1)/CCL2, that may con-
tribute to the cellular inflammatory response [36-38].
These biological effects of TGF support a role for TGF in
chronic cough, at least as a potential explanation for the
remodelling and inflammatory changes observed in the
airway mucosa of chronic cough patients [11]. However,
there is no information as to whether TGF can act as a
sensitiser of the capsaicin cough reflex that is enhanced in
chronic cough. While it is known that TGF exists in at
least 3 isoforms, only the TGF1 isoform has been studied
in the current study. Evaluation of other isoforms is
important as demonstrated with the increased TGF2 iso-
form in a study of patients with severe asthma [39]
The link between TGF and persistent cough is unclear.
Could airway wall remodeling in which TGF is involved
be the basis for the cough? TGF is a growth factor
involved in airway wall remodelling and whether the
fibrotic changes in the airway can alter cough receptor sen-
sitivity is not known. Whether chronic cough leads to air-
way wall remodelling or airway wall remodelling is a
cause of chronic cough is difficult to determine but the
concomitance of both mechanisms may form the basis of
a positive feedback mechanism for cough persistence.
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